2012 in review - Part I: The year's new drugs & biologics

Drugs of Today

Volumn 49, Issue 1, 2013, Pages 33-38

  Graul, A I ^a   Lupone, B ^a   Cruces, E ^a   Stringer, M ^a  

^a THOMSON REUTERS   (United Kingdom)

Author keywords

Line extensions; New approvals; New biologies; New drug launches

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ACLIDINIUM BROMIDE; AFLIBERCEPT; AIMIX; ALIPOGENE TIPARVOVEC; AMINOLEVULINIC ACID; AMLODIPINE BESYLATE; ANGIOTENSIN RECEPTOR ANTAGONIST; ARTESUNATE PLUS PYRONARIDINE; AXITINIB; AZELASTINE PLUS FLUTICASONE PROPIONATE; AZILSARTAN; AZILSARTAN MEDOXOMIL; AZILSARTAN MEDOXOMIL PLUS CHLORTALIDONE; AZILVA; BIOLOGICAL PRODUCT; BIVIGAM; BOSUTINIB; BREEZHALER; BUFYL; BUPIVACAINE; CARBOXYPEPTIDASE G2; CARFILZOMIB; COBICISTAT PLUS ELVITEGRAVIR PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; COMETRIQ; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DAPAGLIFLOZIN; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENZALUTAMIDE; EXCELLAGEN; FENTANYL CITRATE; FLORBETAPIR F 18; FLUOCINOLONE ACETONIDE; FULYZAQ; GABAPENTIN; GABAPENTIN ENACARBIL; GATTEX; GINTUIT; GLUTAMINE; GLYCOPYRRONIUM BROMIDE; HECOLIN; HOMOHARRINGTONINE; HUMAN GROWTH HORMONE; HUNTERASE; HYDROCHLOROTHIAZIDE PLUS METOPROLOL SUCCINATE; ICOSAPENTAENOIC ACID ETHYL ESTER; IMATINIB; INCLUSIG; INFLUENZA VACCINE; INGENOL MEBUTATE; INSULIN ASPART; INSULIN ASPART PLUS INSULIN DEGLUDEC; INSULIN DEGLUDEC; IRBESARTAN; IREMOD; IVACAFTOR; IVERMECTIN; JAPANESE ENCEPHALITIS VACCINE; JUXTAPID; LEVOFLOXACIN; LINACLOTIDE; LINAGLIPTIN PLUS METFORMIN; LORCASERIN; LOSARTAN POTASSIUM; LOXAPINE SUCCINATE; LUCINACTANT; MENHIBRIX; MENINGOCOCCUS VACCINE; MERCAPTAMINE; METOPROLOL SUCCINATE; MIFEPRISTONE; MITOMYCIN; NEPAFENAC; NEW DRUG; OCRIPLASMIN; OPTISOMES; PASIREOTIDE; PERAMPANEL; PERTUZUMAB; PG 201; PHENTERMINE PLUS TOPIRAMATE; PIXANTRONE; PLACEBO; POTELIGEO; POTELLIGENT; PREALBUMIN; QUATTROVAC; REBAMIPIDE; REGORAFENIB; REMESTEMCEL L; SIRTURO; SUPECT; SYNRIAM; TAFAMIDIS; TALIGLUCERASE ALFA; TAPENTADOL; TEDUGLUTIDE; TENELIA; TERIFLUNOMIDE; TESTOSTERONE; TIOTROPIUM BROMIDE; TOFACITINIB; ULIPRISTAL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE SULFATE; VISMODEGIB;

AEROSOL; ANALGESIA; ANESTHESIA; ANTIHYPERTENSIVE THERAPY; BRONCHITIS; BRONCHOSPASM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); CYSTIC FIBROSIS; DIABETIC NEUROPATHY; DIABETIC PERIPHERAL NEUROPATHY; DRUG ABSORPTION; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG INDICATION; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; EPILEPSY; ESSENTIAL HYPERTENSION; FAMILIAL AMYLOID POLYNEUROPATHY; FOOD AND DRUG ADMINISTRATION; FORCED EXPIRATORY VOLUME; HAY FEVER; HUMAN; HYPERTENSION; LENGTH OF STAY; LOW DRUG DOSE; LUNG EMPHYSEMA; MORNING DOSAGE; MULTIPLE SCLEROSIS; NEUROPATHIC PAIN; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; POSTHERPETIC NEURALGIA; POSTOPERATIVE PAIN; PROGNOSIS; PSYCHOPHARMACOLOGY; RESPIRATORY DISTRESS SYNDROME; RESTLESS LEGS SYNDROME; REVIEW; SURVIVAL RATE; SYMPTOM; TONIC CLONIC SEIZURE;

ANIMALS; BIOLOGICAL PRODUCTS; CHEMISTRY, PHARMACEUTICAL; DRUG APPROVAL; DRUG COMBINATIONS; DRUG DISCOVERY; DRUG THERAPY; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 84873633825     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2013.49.1.1933991     Document Type: Review

References (0)